Blueprint reports Phase I data for avapritinib in systemic mastocytosis

Blueprint Medicines Corp. (NASDAQ:BPMC) reported its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of 72% in 18 evaluable patients with advanced systemic mastocytosis (SM) in a Phase I trial.

Read the full 342 word article

User Sign In